Salmaan A. Keshavjee, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 41 | 2023 | 912 | 6.050 |
Why?
|
| Tuberculosis | 29 | 2023 | 1912 | 3.990 |
Why?
|
| Antitubercular Agents | 38 | 2023 | 1320 | 3.700 |
Why?
|
| Tuberculosis, Pulmonary | 13 | 2022 | 810 | 2.540 |
Why?
|
| Mycobacterium tuberculosis | 16 | 2023 | 1832 | 1.610 |
Why?
|
| Latent Tuberculosis | 5 | 2023 | 225 | 1.330 |
Why?
|
| Isoniazid | 7 | 2023 | 274 | 1.190 |
Why?
|
| Communicable Disease Control | 3 | 2021 | 857 | 1.100 |
Why?
|
| Prisoners | 4 | 2023 | 297 | 1.090 |
Why?
|
| Peru | 11 | 2023 | 881 | 1.010 |
Why?
|
| Russia | 12 | 2018 | 408 | 0.850 |
Why?
|
| Tuberculosis, Miliary | 1 | 2020 | 13 | 0.780 |
Why?
|
| Prisons | 2 | 2023 | 161 | 0.720 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 6 | 2015 | 92 | 0.710 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 5319 | 0.660 |
Why?
|
| Contact Tracing | 3 | 2020 | 273 | 0.650 |
Why?
|
| Health Policy | 6 | 2022 | 2661 | 0.570 |
Why?
|
| Health Planning Technical Assistance | 1 | 2014 | 6 | 0.510 |
Why?
|
| Sputum | 4 | 2023 | 476 | 0.500 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 547 | 0.490 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 1738 | 0.460 |
Why?
|
| International Agencies | 2 | 2011 | 240 | 0.450 |
Why?
|
| Human Rights | 1 | 2016 | 307 | 0.450 |
Why?
|
| Silicosis | 1 | 2013 | 45 | 0.440 |
Why?
|
| Mining | 1 | 2013 | 88 | 0.420 |
Why?
|
| Standard of Care | 1 | 2016 | 564 | 0.420 |
Why?
|
| Vaccination | 2 | 2022 | 3278 | 0.420 |
Why?
|
| Disease Notification | 1 | 2012 | 97 | 0.410 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2012 | 121 | 0.390 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 5137 | 0.390 |
Why?
|
| Mass Screening | 7 | 2023 | 5255 | 0.390 |
Why?
|
| Urban Health Services | 1 | 2012 | 179 | 0.390 |
Why?
|
| Disease Outbreaks | 4 | 2012 | 1772 | 0.380 |
Why?
|
| Fluoroquinolones | 6 | 2021 | 310 | 0.370 |
Why?
|
| Health Services Research | 1 | 2018 | 1836 | 0.370 |
Why?
|
| Tuberculin Test | 2 | 2020 | 214 | 0.330 |
Why?
|
| Aviation | 1 | 2008 | 42 | 0.310 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 6489 | 0.300 |
Why?
|
| Humans | 86 | 2023 | 744343 | 0.290 |
Why?
|
| Ethics, Institutional | 1 | 2006 | 37 | 0.290 |
Why?
|
| Pakistan | 5 | 2022 | 295 | 0.290 |
Why?
|
| Transportation of Patients | 1 | 2008 | 185 | 0.290 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 252 | 0.280 |
Why?
|
| Bloodletting | 1 | 2006 | 23 | 0.280 |
Why?
|
| Medicine, Traditional | 1 | 2006 | 91 | 0.260 |
Why?
|
| Health Education | 1 | 2012 | 1056 | 0.260 |
Why?
|
| HIV Infections | 10 | 2016 | 16718 | 0.260 |
Why?
|
| Clinical Medicine | 1 | 2006 | 147 | 0.250 |
Why?
|
| Lesotho | 6 | 2012 | 70 | 0.250 |
Why?
|
| Occupational Diseases | 1 | 2013 | 1471 | 0.240 |
Why?
|
| Rifampin | 3 | 2021 | 315 | 0.240 |
Why?
|
| Program Evaluation | 4 | 2019 | 2488 | 0.240 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2014 | 567 | 0.240 |
Why?
|
| Telemedicine | 1 | 2021 | 2872 | 0.240 |
Why?
|
| Developing Countries | 3 | 2021 | 2815 | 0.230 |
Why?
|
| Economics | 2 | 2006 | 146 | 0.230 |
Why?
|
| National Health Programs | 2 | 2021 | 445 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2019 | 3309 | 0.220 |
Why?
|
| Social Environment | 1 | 2007 | 1023 | 0.210 |
Why?
|
| Program Development | 2 | 2011 | 1316 | 0.210 |
Why?
|
| Blood-Borne Pathogens | 1 | 2001 | 52 | 0.200 |
Why?
|
| Ethics | 1 | 2001 | 94 | 0.200 |
Why?
|
| Deinstitutionalization | 1 | 2021 | 21 | 0.200 |
Why?
|
| Epidemics | 2 | 2019 | 523 | 0.200 |
Why?
|
| Blood Banks | 1 | 2001 | 111 | 0.190 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2023 | 323 | 0.190 |
Why?
|
| X-Rays | 1 | 2021 | 301 | 0.190 |
Why?
|
| Violence | 1 | 2006 | 909 | 0.180 |
Why?
|
| Adolescent | 18 | 2022 | 85781 | 0.180 |
Why?
|
| Socioeconomic Factors | 5 | 2022 | 7785 | 0.180 |
Why?
|
| Directly Observed Therapy | 2 | 2012 | 137 | 0.180 |
Why?
|
| Public Health | 6 | 2022 | 2603 | 0.180 |
Why?
|
| Secondary Prevention | 3 | 2016 | 1530 | 0.180 |
Why?
|
| Community Health Services | 3 | 2021 | 650 | 0.170 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 3158 | 0.170 |
Why?
|
| Social Conditions | 2 | 2013 | 126 | 0.170 |
Why?
|
| Poverty | 2 | 2007 | 2660 | 0.170 |
Why?
|
| Adult | 30 | 2022 | 214055 | 0.160 |
Why?
|
| Social Responsibility | 1 | 2001 | 389 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2004 | 792 | 0.160 |
Why?
|
| Transients and Migrants | 1 | 2021 | 155 | 0.160 |
Why?
|
| Clofazimine | 2 | 2018 | 33 | 0.160 |
Why?
|
| Hemophilia A | 1 | 2001 | 351 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2001 | 547 | 0.160 |
Why?
|
| Family Characteristics | 2 | 2020 | 1000 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 4 | 2023 | 5391 | 0.150 |
Why?
|
| Male | 33 | 2023 | 350118 | 0.150 |
Why?
|
| Health Facilities | 1 | 2022 | 573 | 0.140 |
Why?
|
| Organizational Case Studies | 2 | 2007 | 299 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 14722 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2013 | 1035 | 0.140 |
Why?
|
| Child | 13 | 2021 | 77709 | 0.140 |
Why?
|
| Young Adult | 12 | 2022 | 56430 | 0.140 |
Why?
|
| Treatment Outcome | 16 | 2016 | 63114 | 0.140 |
Why?
|
| World Health Organization | 3 | 2019 | 1318 | 0.140 |
Why?
|
| Child, Preschool | 11 | 2021 | 41006 | 0.140 |
Why?
|
| Social Medicine | 1 | 1996 | 62 | 0.140 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 840 | 0.140 |
Why?
|
| Africa, Southern | 2 | 2013 | 57 | 0.130 |
Why?
|
| Retrospective Studies | 14 | 2019 | 77449 | 0.130 |
Why?
|
| Health Priorities | 1 | 2019 | 380 | 0.130 |
Why?
|
| Female | 30 | 2022 | 380194 | 0.130 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 1439 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2021 | 1462 | 0.120 |
Why?
|
| Leprostatic Agents | 1 | 2014 | 14 | 0.120 |
Why?
|
| Tajikistan | 2 | 2006 | 4 | 0.120 |
Why?
|
| Cohort Studies | 10 | 2021 | 40561 | 0.120 |
Why?
|
| Middle Aged | 17 | 2022 | 213383 | 0.110 |
Why?
|
| Infant | 7 | 2020 | 35136 | 0.110 |
Why?
|
| Virus Replication | 1 | 2021 | 2534 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 1343 | 0.110 |
Why?
|
| Models, Organizational | 2 | 2019 | 574 | 0.110 |
Why?
|
| Health Personnel | 2 | 2021 | 3218 | 0.100 |
Why?
|
| Rural Population | 3 | 2021 | 2210 | 0.100 |
Why?
|
| Occupational Health Services | 1 | 2013 | 154 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2012 | 2740 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2015 | 1184 | 0.100 |
Why?
|
| Aza Compounds | 1 | 2011 | 32 | 0.100 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2214 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 127 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 3923 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 2759 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4933 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2014 | 497 | 0.100 |
Why?
|
| Prevalence | 6 | 2020 | 15226 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2019 | 9849 | 0.090 |
Why?
|
| Recurrence | 3 | 2018 | 8340 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2012 | 720 | 0.090 |
Why?
|
| Disease Progression | 2 | 2019 | 13284 | 0.090 |
Why?
|
| Treatment Failure | 4 | 2018 | 2618 | 0.080 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 1411 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2016 | 1094 | 0.080 |
Why?
|
| International Cooperation | 1 | 2015 | 1420 | 0.080 |
Why?
|
| Aged | 8 | 2021 | 163280 | 0.080 |
Why?
|
| Housing | 1 | 2013 | 664 | 0.080 |
Why?
|
| Algorithms | 2 | 2023 | 13881 | 0.080 |
Why?
|
| Politics | 2 | 2022 | 791 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 847 | 0.080 |
Why?
|
| Risk | 2 | 2016 | 9687 | 0.070 |
Why?
|
| Health Care Costs | 3 | 2012 | 3209 | 0.070 |
Why?
|
| Air Ambulances | 1 | 2008 | 90 | 0.070 |
Why?
|
| USSR | 1 | 2006 | 21 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 971 | 0.070 |
Why?
|
| Symbolism | 1 | 2006 | 34 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2020 | 25625 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1534 | 0.070 |
Why?
|
| Baltimore | 1 | 2006 | 231 | 0.070 |
Why?
|
| Colonialism | 1 | 2006 | 26 | 0.070 |
Why?
|
| Quinolines | 1 | 2011 | 732 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 933 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3508 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2018 | 10252 | 0.060 |
Why?
|
| Logistic Models | 4 | 2022 | 13408 | 0.060 |
Why?
|
| United States | 3 | 2021 | 69872 | 0.060 |
Why?
|
| Infant Care | 1 | 2006 | 183 | 0.060 |
Why?
|
| Haiti | 1 | 2006 | 553 | 0.060 |
Why?
|
| Hospitals | 1 | 2018 | 3952 | 0.060 |
Why?
|
| Decision Making | 2 | 2011 | 3887 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 469 | 0.060 |
Why?
|
| Rwanda | 1 | 2006 | 703 | 0.060 |
Why?
|
| Freedom | 1 | 2023 | 69 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6365 | 0.060 |
Why?
|
| Medication Adherence | 2 | 2012 | 2063 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 941 | 0.060 |
Why?
|
| Time Factors | 3 | 2014 | 40075 | 0.050 |
Why?
|
| Estonia | 2 | 2012 | 53 | 0.050 |
Why?
|
| Motivation | 1 | 2012 | 1971 | 0.050 |
Why?
|
| Child Welfare | 1 | 2006 | 523 | 0.050 |
Why?
|
| Risk Factors | 7 | 2022 | 72290 | 0.050 |
Why?
|
| Capitalism | 1 | 2001 | 15 | 0.050 |
Why?
|
| Alaska | 1 | 2021 | 68 | 0.050 |
Why?
|
| Voluntary Health Agencies | 1 | 2001 | 39 | 0.050 |
Why?
|
| Culture | 1 | 2006 | 633 | 0.050 |
Why?
|
| Anecdotes as Topic | 1 | 2001 | 57 | 0.050 |
Why?
|
| Comorbidity | 2 | 2013 | 10388 | 0.050 |
Why?
|
| Ethambutol | 1 | 2021 | 60 | 0.050 |
Why?
|
| Consumer Advocacy | 1 | 2001 | 81 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 122 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 57776 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39050 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 53288 | 0.050 |
Why?
|
| Incidence | 4 | 2023 | 20947 | 0.040 |
Why?
|
| Computers | 1 | 2022 | 612 | 0.040 |
Why?
|
| Policy | 1 | 2023 | 508 | 0.040 |
Why?
|
| Blood Donors | 1 | 2001 | 355 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 12804 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3528 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 1071 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 3966 | 0.040 |
Why?
|
| Capreomycin | 1 | 2018 | 14 | 0.040 |
Why?
|
| Amikacin | 1 | 2018 | 48 | 0.040 |
Why?
|
| Kanamycin | 1 | 2018 | 64 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2020 | 539 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2016 | 1877 | 0.040 |
Why?
|
| Morals | 1 | 2001 | 284 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 610 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 3022 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 2004 | 950 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7279 | 0.040 |
Why?
|
| Indians, North American | 1 | 2021 | 355 | 0.040 |
Why?
|
| Vitamin D | 2 | 2022 | 3223 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1715 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 2232 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 118 | 0.040 |
Why?
|
| Intelligence | 1 | 2022 | 920 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2006 | 2682 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2019 | 475 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 12354 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 4258 | 0.030 |
Why?
|
| Smoking | 1 | 2012 | 8987 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9313 | 0.030 |
Why?
|
| Physician's Role | 1 | 2001 | 943 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7181 | 0.030 |
Why?
|
| India | 1 | 2020 | 2197 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2020 | 1660 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 21746 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 1584 | 0.030 |
Why?
|
| Latvia | 1 | 2012 | 14 | 0.030 |
Why?
|
| Philippines | 1 | 2012 | 86 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2001 | 1609 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 86 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2001 | 1153 | 0.030 |
Why?
|
| Georgia (Republic) | 1 | 2011 | 41 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2022 | 2050 | 0.030 |
Why?
|
| Pandemics | 2 | 2022 | 8388 | 0.020 |
Why?
|
| ROC Curve | 1 | 2018 | 3527 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5078 | 0.020 |
Why?
|
| Drug Design | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2012 | 12720 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2011 | 438 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2011 | 308 | 0.020 |
Why?
|
| Curriculum | 1 | 2021 | 3605 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3589 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3749 | 0.020 |
Why?
|
| Cross Infection | 1 | 2015 | 1416 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2020 | 23338 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2011 | 687 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2020 | 9146 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 1683 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8642 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 2026 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1850 | 0.010 |
Why?
|
| Data Collection | 1 | 2012 | 3341 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15076 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 1199 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2011 | 2616 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2011 | 2531 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 7023 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12245 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29063 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4386 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 18370 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7913 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 19905 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 29144 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12959 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 9856 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 3584 | 0.010 |
Why?
|